Inventor · disambiguated record
Qi Liang
Also filed as: LIANG QI · LIANG QI FENG
25 granted patents·32 pending applications·404 citations·filing 2011–2023
97Inventor score
Top patents by PatentIndex Score
57 records- 0198US9447177B2Transgenic mouse homozygous for chimeric IgH locusBRADLEY ALLAN·Filed 2012·Granted Sep 20, 2016·36 cites·6 claims
- 0298US9434782B2Animal models and therapeutic moleculesKYMAB LTD·Filed 2013·Granted Sep 6, 2016·31 cites·8 claims
- 0397US10226033B2Animal models and therapeutic moleculesKYMAB LTD·Filed 2017·Granted Mar 12, 2019·13 cites·22 claims
- 0497US10165763B2Animal models and therapeutic moleculesKYMAB LTD·Filed 2013·Granted Jan 1, 2019·13 cites·16 claims
- 0597US9938357B2Animal models and therapeutic moleculesKYMAB LTD·Filed 2016·Granted Apr 10, 2018·21 cites·23 claims
- 0697US9938358B2Animal models and therapeutic moleculesKYMAB LTD·Filed 2016·Granted Apr 10, 2018·19 cites·23 claims
- 0797US9924705B2Animal models and therapeutic moleculesKYMAB LTD·Filed 2016·Granted Mar 27, 2018·20 cites·36 claims
- 0897US9896516B2Animal models and therapeutic moleculesKYMAB LTD·Filed 2016·Granted Feb 20, 2018·20 cites·11 claims
- 0997US9505827B2Animal models and therapeutic moleculesKYMAB LTD·Filed 2013·Granted Nov 29, 2016·27 cites·10 claims
- 1097US9445581B2Animal models and therapeutic moleculesBRADLEY ALLAN·Filed 2012·Granted Sep 20, 2016·51 cites·27 claims
- 1196US10774155B2Animal models and therapeutic moleculesKYMAB LTD·Filed 2018·Granted Sep 15, 2020·9 cites·26 claims
- 1296US10064398B2Animal models and therapeutic moleculesKYMAB LTD·Filed 2014·Granted Sep 4, 2018·14 cites·25 claims
- 1396US9788534B2Animal models and therapeutic moleculesKYMAB LTD·Filed 2013·Granted Oct 17, 2017·18 cites·19 claims
- 1496US9253965B2Animal models and therapeutic moleculesBRADLEY ALLAN·Filed 2012·Granted Feb 9, 2016·35 cites·23 claims
- 1595US9504236B2Animal models and therapeutic moleculesKymab Limited; The Bennet Building (B930)·Filed 2015·Granted Nov 29, 2016·29 cites·15 claims
- 1692US9963716B2Chimaeric surrogate light chains (SLC) comprising human VpreBKYMAB LTD·Filed 2014·Granted May 8, 2018·12 cites·38 claims
- 1789US2023263143A1Animal Models and Therapeutic MoleculesKYMAB LTD·Filed 2023·Application pending·0 cites
- 1889US2023225302A1Animal Models and Therapeutic MoleculesKYMAB LTD·Filed 2023·Application pending·0 cites
- 1987US2023270088A1Animal Models and Therapeutic MoleculesKYMAB LTD·Filed 2022·Application pending·0 cites
- 2087US2024057572A1Animal Models and Therapeutic MoleculesKYMAB LTD·Filed 2022·Application pending·0 cites
- 2186US10337000B2Expression vector production and high-throughput cell screeningKYMAB LTD·Filed 2014·Granted Jul 2, 2019·4 cites·16 claims
- 2284US11606941B2Animal models and therapeutic moleculesKYMAB LTD·Filed 2016·Granted Mar 21, 2023·1 cites·20 claims
- 2383USD850029SLitter boxMODPRODUCTS LLC·Filed 2017·Granted May 28, 2019·25 cites·1 claims
- 2482US11066464B2Anti-malarial antibodies that bind circumsporozoite proteinKYMAB LTD·Filed 2018·Granted Jul 20, 2021·4 cites·13 claims
- 2581US11564380B2Animal models and therapeutic moleculesKYMAB LTD·Filed 2015·Granted Jan 31, 2023·1 cites·34 claims
- 2680US11297810B2Animal models and therapeutic moleculesKYMAB LTD·Filed 2019·Granted Apr 12, 2022·1 cites·31 claims
- 2780US2023159660A1Animal models and therapeutic moleculesKYMAB LTD·Filed 2022·Application pending·0 cites
- 2878US2020352145A1Animal Models and Therapeutic MoleculesKYMAB LTD·Filed 2020·Application pending·0 cites
- 2978US2020337280A1Animal Models and Therapeutic MoleculesKYMAB LTD·Filed 2020·Application pending·0 cites
- 3077US2020375158A1Animal Models and Therapeutic MoleculesKYMAB LTD·Filed 2020·Application pending·0 cites
- 3177US2020352144A1Animal Models and Therapeutic MoleculesKYMAB LTD·Filed 2020·Application pending·0 cites
- 3277US2022287283A1Animal models and therapeutic moleculesKYMAB LTD·Filed 2022·Application pending·0 cites
- 3375US2021079118A1Animal models and therapeutic moleculesKYMAB LTD·Filed 2020·Application pending·0 cites
- 3474US2023049767A1Expression vector production and high-throughput cell screeningKYMAB LTD·Filed 2022·Application pending·0 cites
- 3572US11812731B2Animal models and therapeutic moleculesKYMAB LTD·Filed 2013·Granted Nov 14, 2023·0 cites·13 claims
- 3672US2017105396A1Animal Models and Therapeutic MoleculesKYMAB LTD·Filed 2016·Application pending·0 cites
- 3771US2014201854A1Animal models and therapeutic moleculesKYMAB LTD·Filed 2013·Application pending·0 cites
- 3871US2014201856A1Animal models and therapeutic moleculesKYMAB LTD·Filed 2013·Application pending·0 cites
- 3971US2017051045A1Animal models and therapeutic moleculesKYMAB LTD·Filed 2016·Application pending·0 cites
- 4071US2017101482A1Animal Models and Therapeutic MoleculesKYMAB LTD·Filed 2016·Application pending·0 cites
- 4171US2017099817A1Animal Models and Therapeutic MoleculesKYMAB LTD·Filed 2016·Application pending·0 cites
- 4271US2017099815A1Animal Models and Therapeutic MoleculesKYMAB LTD·Filed 2016·Application pending·0 cites
- 4370US2017071174A1Animal models and therapeutic moleculesKYMAB LTD·Filed 2016·Application pending·0 cites
- 4470US2017099816A1Animal models and therapeutic moleculesKYMAB LTD·Filed 2016·Application pending·0 cites
- 4570US2017094956A1Animal models and therapeutic moleculesKYMAB LTD·Filed 2016·Application pending·0 cites
- 4669US2016345551A1Animal models and therapeutic moleculesKYMAB LTD·Filed 2016·Application pending·0 cites
- 4769US2015113669A1Animal Models and Therapeutic MoleculesKYMAB LTD·Filed 2014·Application pending·0 cites
- 4868US11371042B2Expression vector production and high-throughput cell screeningKYMAB LTD·Filed 2019·Granted Jun 28, 2022·0 cites·19 claims
- 4967US2016150768A1Animal Models and Therapeutic MoleculesKYMAB LTD·Filed 2016·Application pending·0 cites
- 5067US2016044900A1Animal models and therapeutic moleculesKYMAB LTD·Filed 2015·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Qi Liang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →